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Antibody  responses  can  be  induced  in  vitro from  B  cell populations with  a 
variety of stimuli,  provided that T  cells or various cytokines are present in the 
cultures.  In  most  studies,  initial  signals  for B  cell activation are generated  via 
immunoglobulin  (Ig)  receptors  and  are  mediated  by  antigens  or  by  anti-Ig 
antibodies (1-4). Subsequent B cell proliferation and differentiation to antibody- 
secreting cells is greatly augmented by the presence of soluble mediators gener- 
ated in  cultures containing activated T  cells.  Early studies  described a  T  cell- 
replacing factor (TRF), ~ present in supernatants (Sn) of murine mixed leukocyte 
reactions (MLR), that supported antibody responses of spleen cells from nu/nu 
mice to sheep red blood cells (SRBC) (5).  Subsequent work revealed a  similar 
activity in  Sn  of concanavalin  A  (Con  A)-stimulated  spleen  cells  that  was  not 
active on cells from mice with the xid defect (6). Similar TRF activity for murine 
B cells has been shown with human  MLR Sn (7), suggesting that the mediators 
can also function across species barriers. 
Early efforts to characterize the molecular components of TRF met with little 
success, possibly because several mediators cooperated in  the biological assays. 
Recent work has attempted to analyze the specific cytokines using Sn of mono- 
clonal or long-term  T  cell lines and  lympbokine fractions of known biological 
activity.  Results  from  these  studies  (8-10)  show  that  at  least  two  different 
lymphokine preparations act synergistically to produce a  TRF effect on B cells 
in plaque-forming cell (PFC) responses driven either by antigen or anti-Ig.  One 
of the complementing components is usually obtained from T  cell hybridomas, 
and  contains  interleukin  2  (IL-2). The other is obtained in Sn  of a  long-term 
alloreactive T  cell line or some T-T hybridomas, and contains several biological 
activities,  including  3'  interferon (IFN-3").  It  is  termed  T  cell-replacing  factor 
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(TRF) or interleukin X  (IL-X) (11) and is active in responses to hapten-carrier 
antigens (12) as well as thymus-independent antigens (13). It is possible, however, 
that  both  Sn  contain  other  mediators  which  may contribute  to  the  antibody 
responses; some studies indicate that interleukin 1 (IL-1) (11) and perhaps other 
factors (10)  may be  required  to obtain maximum TRF activity. However,  the 
precise role for any of these factors in the antibody response is not known and 
the target cells for their actions remain to be identified. 
Results from some recent studies have suggested that IFN-3, may be a  com- 
ponent of TRF. Indirect evidence was obtained from the acid-labile character of 
TRF present in antigen- or Con A-stimulated T  cell Sn (1,  12) and also from a 
correlation of IFN-3, levels and TRF activity of Sn of T  cell hybridomas (14). 
This view is supported  by recent data (15)  showing that recombinant-derived 
murine IFN-3' (Mu rIFN-3') can act as the second component of a complementing 
TRF system to support PFC responses to antigen (15).  However, the specificity 
of the IFN-y effect is unclear since it may also act as a polyclonal activator for B 
cell  PFC responses  (16).  Together,  the  data suggest that  purified IFN-3,  may 
modulate B cells in their maturation to antibody production, but it is not clear 
whether this is accomplished through the pathway normally regulated by TRF. 
Similarly, it is  possible that Con A  or MLR Sn contain other TRF mediators, 
distinct from IFN-3', which could independently support PFC responses. 
In the present study, we have tested whether IFN-'y is essential in the TRF 
activity of four  independent  TRF  preparations,  including two  derived  from 
primate  cells.  We  added  to  the  cultures  an  antibody to  IFN-3,  that has  been 
shown (17,  18)  to neutralize the biological activity of IFN-'r  in antiviral assays 
and  macrophage  activation  assays;  similar  inhibitory  effects  have  also  been 
obtained in Ia antigen induction systems (19). The results clearly show that IFN- 
is a  required mediator in the action of several forms of TRF, that it only acts 
relatively early in the response, and that, in cases of TRF which lack this factor, 
the IFN-3' is produced by the responding ceils, despite extensive T  cell depletion. 
The source of the IFN-~' may be the natural killer (NK) cells produced in these 
cultures. 
Materials and Methods 
Mice.  (DBA/2  x  CBA/N)F1  and the reciprocal  hybrid mice were purchased  from 
Dominion Laboratories, Dublin,  VA and outbred nude mice (nu/nu) were purchased 
from Charles River Breeding Laboratories, Wilmington, MA. CBA/J mice were purchased 
from The Jackson  Laboratory, Bar Harbor,  ME and BALB/c mice from Cumberland 
View Farms, Clinton, TN. All mice were 5-12 wk old when used. 
Antigens and Other Reagents.  SRBC were obtained from a single animal (B1) from the 
Navy Medical  Research  Institute,  Bethesda,  MD;  burro  red blood cells  (BRBC)  were 
purchased from Colorado Serum Co.,  Denver, CO.  Con A was purchased from Difco 
Laboratories, Inc., Detroit, Mi and alpha-methyl-n-mannoside from Sigma Chemical Co., 
St. Louis, MO. A human lymphokine-rich fraction, termed purified IL-2, was purchased 
from Electro-Nucleonics, Inc., Silver  Spring, MD [TRF(E-N)].  B cells were prepared in 
RPMI  1640  supplemented with 2 ml L-glutamine, 25 mM Hepes, 50/~g/ml gentamycin 
sulfate, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 #g/ml streptomycin, and 10% 
heat-inactivated fetal calf serum (Tissue Culture Biologicals, Tulane, CA). The medium 
for cell cultures also contained 5 x  10  -~ M 2-mercaptoethanol and fetal calf serum from 
a selected lot (Biofluids Inc., Rockville, MD). Mu rIFN-3, and recombinant-derived human BRUNSWICK AND  LAKE  955 
IFN-3" (Hu rlFN-3") were kind gifts of Dr. C. Sevastopolous, Genentech, Inc., South San 
Francisco. 
Murine TRF.  Murine  TRF  was prepared as described  (5).  Spleen cells from CBA/~ 
and BALB/c mice were mixed in equal numbers to produce a final concentration of 113' 
cells/mi. The cells were cultured for 24 h  and cell-free Sn were collected and stored at 
-80°C. A  Con A-stimulated Sn was prepared as described (8).  Briefly, spleen cells from 
(DBA/2 ×  CBA/N)F1  mice were cultured at  107 cells/ml in the presence of 4  ~g/ml of 
Con A. After 24 h, cell-free Sn were collected and stored at -80°C. When Con ASn was 
used,  10 mg/ml of alpha-methyl-D-mannoside was added to all cultures. 
Antisera.  Antithymocyte serum  (ATS)  was  prepared  from rabbits  hyperimmunized 
with mouse thymocytes; IgM monoclonal antibody to Thy-l.2 (clone F7D5) was used at a 
final concentration of 1:1000; rabbit anti-mouse IFN-3' (RAM-IFN-3,) (rabbit MI-3) and 
rabbit anti-human IFN-3, (RAH-IFN-3,) (rabbit  12R 1) were prepared exactly as described 
by  Svedersky  et  al.  (18).  Briefly,  rabbits  were  immunized  with  rlFN-3,  expressed  in 
Escherichia coil that had been purified to the extent described earlier (20, 21), in complete 
Freund's adjuvant (200 ug protein  in six subcutaneous sites).  Afer  10 d, the same dose 
was given intramuscularly in incomplete  Freund's adjuvant; after 20 d,  200 #g protein 
was given intravenously. On day 24 the rabbit was bled. The affinity-purified RAM-IFN- 
3' was the same preparation used by Svedersky et al. (18) and its preparation was described. 
Briefly,  12 mg of highly purified Mu rlFN-3" were coupled to Affi-gel 10 resin;  2 ml of 
hyperimmune rabbit antiserum to Mu rlFN-3" was applied; and bound material was eluted 
with a  sodium citrate buffer, pH  3.0.  These antisera  were kind gifts of Dr.  C.  Benton, 
Genentech,  Inc. The interspecies  rat monoclonal antibody to Mu  IFN-3" R4-6A2 was a 
generous gift of Dr. E. A. Havell, and was supplied as a tissue culture Sn. 
T-depleted  Spleen  Cell Preparations.  To  prepare  B  cell-enriched  populations,  unim- 
munized mice were inoculated intraperitoneally with 0.05 ml ATS 2 d before harvesting 
of the spleens. The spleen cell suspension was washed three times and resuspended at one 
spleen equivalent per 5 ml medium containing anti-Thy-1.2 antibody and rabbit comple- 
ment (C') (Hazleton Dutchland, Inc., Denver, PA) diluted 1:15. The cells were incubated 
for 45  min at  37°C and collected by centrifugation,  and  the  treatment  repeated.  The 
cells  were then  resuspended  in  2.5  mi of complete medium,  and plastic-adherent  cells 
(two spleen equivalents per dish) were depleted by incubation at 37°C for 2 h in  10-cm- 
diam petri  dishes  (Costar,  Data  Packaging Corp.,  Cambridge,  MA).  Nonadherent  cells 
were recovered by gentle flushing of the dishes and resuspended at I  ml per yield of one 
petri  dish.  This volume was applied  at room temperature  to a  Sephadex  G-10 column 
equilibrated  with  medium  (22).  Effluent  cells  were  collected  by centrifugation,  resus- 
pended in complete medium, and counted before use. 
Cell  Culture.  B  cell  responses  were  generated  in  96-well,  fiat-bottom  microculture 
plates  (Costar)  at a  density of 106 B  cells per well,  in  0.2  ml of medium  with  2  ×  106 
SRBC. PFC were usually counted after 4 d. Results are expressed as the arithmetic mean 
___ SEM of triplicate  cultures unless otherwise stated  (for controls, six replicate  cultures 
were prepared). TRF(E-N) was normally used at a final concentration of 20%. IL-I, from 
24 h  Sn of silica-stimulated,  plastic-adherent human peripheral blood mononuclear cells, 
was added to all cultures at a final concentration of 5  U/ml, as optimized in preliminary 
experiments. 
RBC Plaque Assay.  PFC per culture were determined by following previously described 
methods  (23).  Briefly, cultures  were sedimented  by centrifugation  and resuspended  in 
0.25 ml of complete medium.  0.025  ml of the cell suspension was combined with equal 
volumes of medium, a 5% SRBC suspension, and absorbed (10% vol SRBC or 20% BRBC 
for  1 h  at  0°C) guinea pig complement,  diluted  1:2.  Loaded Cunningham slides were 
incubated at 37°C for 30 min and PFC were counted. 
NK Cell Assay.  After 4  d  of culture,  cells were collected and tested  for NK activity 
with in vitro propagated YAC-1 or P-388D~ cells labeled with 5~Cr. Percent specific release 
was calculated in the standard  manner as percent specific lysis =  [(experimental  cpm - 
spontaneous release cpm)/(total cpm -  spontaneous release cpm)] X 100. Lytic units were 
determined by interpolation of the dose response curve for the effector/target (E/T) ratio 056  7  INTERFERON  ROLE  IN  T  CELL-REPLACING FACTOR  ACTION 
that produced 30%  lysis. The activity of each population is expressed as the number of 
lytic units per  10  7 effector cells. For example, I0 lytic units is equivalent to 7.5% specific 
lysis of target cells at an E/T ratio of 25:1. 
Results 
TRF Activity of an IL-2-rich Lymphokine Fraction.  In preliminary experiments 
we found that a  mitogen-free fraction of the  Sn of activated human peripheral 
blood mononuclear cells (PBMC),  termed TRF(E-N), acted as a  potent TRF for 
murine spleen cells.  The cells were prepared from mice that had received ATS 
in vivo, and were treated twice with monoclonal anti-Thy- 1.2 and C' and depleted 
of plastic- and  Sephadex  G-10-adherent  cells.  As  shown  in  Fig.  1,  TRF(E-N) 
reconstituted the PFC response to SRBC of splenic B cells from (DBA/2 ×  CBA/ 
N)Fl male mice but not that of the reciprocal hybrid. TRF(E-N) showed consid- 
erable  helper  activity at  concentrations  of  1-5%  in  the  culture  and  was  only 
moderately dependent  on  the addition  of exogenous  IL-1, perhaps because of 
the  cell  density  of the  cultures.  In  almost all  experiments,  the  above methods 
produced high PFC responses to SRBC, generally 1,000-1,500  PFC per culture. 
Similar results were obtained after more stringent T  cell depletions, in addition 
to the ones described.  These included  in vivo and  in vitro treatment with anti- 
asialo  GM~  serum,  and  in  vitro  treatment  with  monoclonal  anti-Lyt-1,  -Lyt-2, 
-Qa-4, and -Qa-5 antibodies in  the presence of appropriate enhancing sera and 
C', followed by B cell enrichment  by positive selection for Ig-bearing cells (not 
shown). As shown below, PFC responses that were supported by TRF(E-N) were 
fully antigen specific and were also generated with spleen cells from nu/nu  mice 
(not shown). Thus, human TRF(E-N) exhibits properties concordant with those 
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FIGURE 1.  Response of normal and immunodeficient CBA/N hybrid mice to human-derived 
TRF(E-N) and the effect of IL-i. T-depleted spleen cells were prepared from (DBA/2 X CBA/ 
N)FI (A) or (CBA/N x DBA/2)FI (11) male mice and cultured for 4 d in the presence of SRBC, 
2 X 106 per well, and TRF(E-N). IL-1 at 1.0 U per culture was added to the (DBA/2 × CBA/ 
N)FI (0) and (CBA/N × DBA/2)FI culture.  No PFC were obtained with the latter group in 
the absence of IL-1. Direct PFC to SRBC were determined  at 4 d and expressed as the mean 
of triplicate cultures +_ SEM. Control values, mean (SEM): spleen cells alone, 3 (3); plus SRBC, 
0; plus TRF(E-N), 7 (7). BRUNSWICK  AND  LAKE  957 
Rabbit Antiserum to Mu IFN-3" Inhibits TRF(E-N) Action.  The requirement for 
IFN-3' as a  mediator  in  these spleen  cell  responses was tested by adding  to  the 
cultures  a  hyperimmune  rabbit  antiserum  to  highly  purified  Mu  rIFN-3'.  As 
shown  in  Fig.  2,  the  addition  of  5%  rabbit  antiserum  to  Mu  IFN-3"  totally 
inhibited  the production  of PFC.  A  substantial  inhibition  was still seen at 0.2% 
(1:500).  The  IFN-3"-neutralizing  activity  at  this  latter  dilution  was  25  U  per 
microculture  (0.20  ml),  which  was selected for routine  use in  most subsequent 
experiments for reasons of economy. Control  rabbit serum, obtained from the 
same animal  before  immunization,  was  inactive,  and  serum  from a  rabbit  im- 
munized to Hu rIFN-3" (8 x  104 neutralizing U/ml) also had no effect. 
Inhibition of Murine TRF(E-N) by Specific Ig or Monoclonal Antibody and Reversal 
With Mu  rlFN-3,.  Confirmation  that antibody to  IFN-3, was the active compo- 
nent in the antiserum to IFN-3, was obtained with an affinity-purified antibody 
eluted  from  a  column  of insolubilized  Mu  rIFN-3'.  As  shown  in  Table  I,  the 
addition  of purified  anti-IFN-3" antibody  inhibited  responses  of spleen  B  cells 
whereas normal rabbit Ig did not. In this experiment TRF from a  murine MLR 
as well as the human-derived TRF(E-N) were inhibited by antibody to Mu IFN- 
3'. 
It  was  postulated  that  abrogation  of the  PFC  response  was  caused  by  the 
quantitative neutralization of natural IFN-3" activity, which was required for PFC 
responses.  Such  a  mechanism should be reversible upon the addition  of excess 
IFN-% This was tested by adding purified rIFN-3" to the cultures (Table II). The 
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FIGURE 2.  Inhibition of TRF-induced  PFC by antiserum  to Mu IFN-% T-depleted spleen 
cells from (DBA/2 x  CBA/N)F~ mice were cultured  for 4 d in the presence 20% TRF(E-N) 
and SRBC. Rabbit  antisera  were added  at the  start of the cultures  at the indicated  final 
dilution. The sera are from (I) rabbit MI-3 before immunization, (O) rabbit MI-3 hyperim- 
munized with Mu rlFN--r, and (A) rabbit  12R1 hyperimmunized  with Hu rlFN-3,. A  1:20 
dilution  of M1-3 antiserum  is equivalent to 625  IFN-3' viral neutralizing  units per culture. 
Control values: spleen cells alone, 0; plus SRBC, 13 (8); plus TRF(E-N), 16 (4); plus TRF(E- 
N) and SRBC, 1,363 (211). 958  "r  INTERFERON  ROLE  IN  T  CELL-REPLACING FACTOR  ACTION 
TABLE  I 







PFC per culture (SEM) 
TRF (MLR)  TRF(E-N) 
SRBC  0  1,087 (92)  1,038 (42) 
SRBC  250  57 (17)  O0 (12) 
SRBC  83  423 (84)  667 (58) 
SRBC  28  613 (52)  893 (132) 




SRBC  1.000  1,060 (49)  907 (66) 
--  --  lO  (6)  55  (lO) 
Murine  T-depleted spleen cells were  prepared as described  in  Materials and 
Methods except plastic adherence  and Sephadex passage was omitted.  106 cells 
were cultured for 4 d in the presence of 25% murine or 20% human TRF(E-N) 
Sn. Immunospecifically purified antibody to Mu rlFN-7 was added at the start 
of the cultures. MLR Sn was the supernatant  of a 24 h murine MLR. Antibody 
was present from the start of the cultures and had 10 U of antiviral neutralizing 
activity per 100 ng. 
PFC  responses  that  were  supported  by  either  murine  or  human  TRF  were 
strongly inhibited in a dose-dependent fashion by antiserum or purified antibody 
to IFN-3,. These inhibited responses were substantially or fully reconstituted by 
the addition of 2,500  U  of Mu rIFN-3,. 
The stoichiometry of the anti-IFN-3, effect was examined in greater detail in 
a  dilution  analysis of both the antiserum to Mu  IFN-3, and the rlFN-3, that was 
added to the cultures.  A  comparison of the inhibitions caused by 25 and  125  U 
of antiserum (Table III) indicates that, with lower doses of antibody, recovery is 
more readily obtained when a similar amount of IFN-3, is used. The addition of 
IFN-3,  to  TRF-containing  cultures  in  separate  experiments  had  no  effect  on 
TRF-mediated responses.  Suprisingly,  IFN-3, also failed to augment  weak  PFC 
responses induced  by suboptimal  concentrations  of TRF,  suggesting  that  some 
other cytokine was limiting in the system (Tables IV and V). 
It is also important (Table III and Fig. 2) that antiserum to human IFN-3, has 
little or no  inhibitory  activity, and  that  human  rIFN-3, cannot  reconstitute  the 
inhibited  response,  although  it  significantly  augments  the  PFC  response  of 
noninhibited  cultures.  Thus the activity of human-derived TRF(E-N) cannot be 
explained by its content  of Hu  IFN-3,. The Sn of the  Gibbon lymphoma MLA- 
144,  which  constitutively produces  IL-2, exhibited  high  TRF  activity in  these 
cultures  (Table  V).  Addition  of antibody  to  Mu  IFN-3,  inhibited  those  PFC 
responses.  The responses were restored by the addition  of 2,500  U  of rIFN-'/. 
No  direct  TRF  effects  of rIFN-'y alone  were  detected  in  these  studies.  Very 
recently  (17)  a  monoclonal  antibody  to  Mu  IFN-3,  was  generated  that  can 
functionally  neutralize  the  biological  properties  of IFN-3,.  When  added  to  the BRUNSWICK  AND  LAKE  959 
TABLE  II 
Antiserum or Specific Antibody to IFN-'y Inhibits the Action of Human 
TRF(E-N) or Murine (Con A) TRF on B Cell Responses to SRBC and 
Reversal of the Effect with Mu rlFN-3, 
Addi- 
Antiserum  tion of 
PFC to SRBC per 
Experiment  1  Antigen  to murine  Mu  culture (SEM) of 
TRF  IFN-3,  rlFN-3,  106 B cells 
(units)  (2,500 
u) 
Con A/Sn  SRBC  0  -  1,020 (70) 
Con A/Sn  SRBC  50  -  157 (35) 
Con A/Sn  SRBC  6.3  -  203 (77) 
Con A/Sn  SRBC  3.1  -  313 (72) 
Con A/Sn  SRBC  1.6  -  290 (100) 
Con A/Sn  SRBC  0.8  -  583 (198) 
Con A/Sn  SRBC  0  -  920 (52) 
Con A/Sn  SRBC  25  -  210 (55) 
Con A/Sn  SRBC  25  +  730 (107) 
Con A/Sn  No SRBC  0  -  25 (9) 
TRF(E-N)  SRBC  0  -  967 (I 11) 
TRF(E-N)  SRBC  25  -  423 (50) 
TRF(E-N)  SRBC  25  +  935 (72) 
TRF(E-N)  No SRBC  0  -  12 (6) 
None  SRBC  0  -  7 (2) 
Purified an-  Addition 
Experiment 2  Antigen  tibody to  of Mu  PFC to SRBC per 
TRF  Mu IFN-~,  rlFN-~,  culture (SEM) of 
106 B cells 
(ng)  (2,500 U) 
TRF(E-N)  SRBC  0  -  1,290 (64) 
TRF(E-N)  SRBC  1,000  -  87 (33) 
TRF(E-N)  SRBC  500  -  267 (101) 
TRF(E-N)  SRBC  250  -  557 (142) 
TRF(E-N)  SRBC  125  -  883 (151 ) 
TRF(E-N)  SRBC  63  -  1,013 (219) 
TRF(E-N)  SRBC  500  +  1,243 (87) 
Normal rab- 
bit Ig (ng) 
TRF(E-N)  SRBC  1,000  -  1,350 (53) 
None  SRBC  0  -  0 
None  None  0  -  0 
TRF(E-N)  None  0  -  23 (12) 
T-depleted spleen cells were cultured at 106 cells per microculture for 4 d  in the 
presence of 25%  murine Con A  Sn or 20%  human TRF(E-N) Sn. Mu rlFN-3,, 
(Exps.  1 and  2),  rabbit  antiserum  (Exp.  1),  or  immunospecifically purified  Ig 
(Exp. 2) were added at the indicated concentration per well, at the initiation of 
the cultures. 1,000 ng of antibody had 100 antiviral neutralizing units of activity. 960  -y  INTERFERON  ROLE  IN  T  CELL-REPLACING  FACTOR  ACTION 
TABLE  III 
Dose Response Analysis of Inhibition of TRF Activity by Antibody to Mu IFN-~ and Recovery of 
Response by Addition of rlFN-~ 
Direct PFC to SRBC per culture (SEM) 
TRF(E-N) plus  Source of  Units of  No anti-  TRF(E-N) plus antibody to Mu  antibody to Hu 
rIFN-~'  body  IFN-7  rI FN-~  added  I FN-7 
25 U  125 U  125 U 
Murine  0  0  457 (135)  247 (28)  1,083 (50) 
2.5  0  337 (58)  307 (93)  1,053 (107) 
25  17 (17)  430 (50)  360 (106)  1,787 (527) 
250  13 (12)  860 (111)  293 (47)  1,640 (280) 
2500  13 (9)  1,263 (142)  1,000 (27)  1,657 (303) 
Human  0  0  497 (154)  327 (55)  1,277 (274) 
2.5  0  377 (88)  297 (29)  1,693 (124) 
25  6 (6)  353 (160)  247 (43)  1,467 (162) 
250  3 (3)  280 (26)  220 (30)  2,027 (135) 
2500  17 (17)  387 (33)  257 (29)  2,320 (183) 
Controls: SRBC plus TRF(E-N) 1,474  (80) 
SRBC only  0 
T-depleted spleen cells were cultured for 4 d  in the presence of SRBC and TRF(E-N). Antibody 
and/or rIFN-3' were added at the start of the cultures. Amounts of antibody and IFN-7 added are 
expressed in units per 0.2 ml culture. 
TABLE  IV 
rlFN-~, Lacks TRF Activity and Does Not Complement Limiting Concentrations of TRF(E-N) 
for PFC Responses 
PFC (SEM) per culture 
Units of Mu  Percent TRF(E-N) per culture: 
rIFN-3" 
0  2.5  5  10  20 
2,500  20 (12)  770 (106)  867 (96)  1,437 (108)  1,400 (202) 
250  7 (7)  853 (87)  893 (107)  1,533 (81)  1,187 (78) 
25  10 (6)  817 (64)  1,073 (47)  1,300 (126)  1,487 (94) 
2.5  20 (10)  913 (62)  1,073 (108)  1,163 (231)  1,373 (54) 
0  90 (25)  967 (52)  1,260 (31)  1,327 (153)  1,450 (130) 
10  n T-depleted spleen cells were placed in culture with 2 ×  106 SRBC. TRF(E-N) and Mu rlFN-T 
were added to the cultures as indicated. PFC were determined after 4 d. Results are expressed as 
mean PFC (SEM) per culture. Control values: None, 3 (2); plus TRF(E-N), 17 (5). 
TRF  assay, this antibody showed potent inhibitory effects (Table VI) which were 
reversed by the addition of excess Mu rIFN-"r. 
Specificity of the PFC Responses After Reversal of Antibody Block by rlFN-7.  The 
PFC responses supported  by TRF(E-N)  were shown in preliminary studies to be 
antigen  specific.  However,  it was  possible that  the  PFC responses produced  by 
the reversal of anti-IFN-3, antibody by excess rIFN-3, were not antigen specific, 
and could have been  due to polyclonai B  cell activation by rIFN-%  The  results BRUNSWICK  AND  LAKE 
TABLE  V 
Constitutive Production of TRF by a Primate Lymphoma MLA-144 
961 
PFC per culture (SEM) 
Percent of 
Plus anti-  Plus anti-IFN-~,,  MLA-144  Plus rI FN-~, 
Sn  Plus SRBC  and SRBC  IFN-~, and  rIFN-~,, and 
SRBC  SRBC 
25  1,043 (43)  943 (203)  310 (70)  1,060 (128) 
12.5  840 (108)  623 (60)  143 (47)  537 (223) 
6.25  230 (60)  177 (102)  40 (10)  350 (125) 
Controls 
None  2 (2) 
TRF(E-N)  1,267 (60) 
B  B 
106 T-depleted spleen cells were cultured for 4  d  in the presence of MLA-144 
Sn. rlFN-3, (2,500 U) and/or RAM-IFN-~, (25 neutralizing units) was added to 
indicated cultures. Direct PFC were determined and the results expressed as the 
mean (SEM) of triplicate cultures. 
TABLE  VI 
Inhibition of TRF Activity by Monoclonal Antibody to Mu 1FN-~ and 
Recovery of the Response With rlFN-~, 
Source of rlFN-~"  Culture Sn 
(2,500 U)  dilution 
Direct PFC (SEM) to SRBC per culture 
Monoclonal R4-6A2  Culture Sn of spent 
Sn to Mu IFN-~,  NS-1 cells 
None  5×  87 (29)  1,163 (159) 
None  1×  417 (78)  1,187 (73) 
Murine  5x  1,140 (241)  ND* 
Murine  l×  1,290 (145)  ND 
Controls: SRBC plus TRF(E/N)  1,310 (105) 
SRBC only  2  (2) 
T-depleted spleen cells were cultured for 4  d  in the presence of SRBC and 
20% TRF(E-N).  Sn from the monoclonal line R4-6A2 or from the myeloma 
P3/NS-1/1-Ag4-1  were used neat or were concentrated 5X using a Centricon 
10 membrane (Amicon Corp., Danvers, MA). At the start of incubation some 
cultures also received Mu rIFN-~,. 
* Not done. 
of an experiment using SRBC or BRBC antigens (Table VII) show that both the 
uninhibited and the recovered responses are fully antigen specific. 
TRF Induces IFN-'y Production and Potent NK Activity  in T-depleted  Spleen  Cell 
Cultures.  The preceding experiments suggest that IFN-~, is produced in cultures 
of T-depleted murine spleen cells. This was directly tested using Sn from spleen 
cells cultured in various conditions (Table VIII). The data demonstrate that IFN- 
3' is produced only in cultures stimulated with TRF(E-N) and can be detected on 
day 3, although  levels below the sensitivity of the antiviral assay may be present 
at earlier times.  Antiserum  to IFN-'y, but not to IFN-a and -t3, abolished both 
the IFN antiviral activity and the PFC response. 
Since B cell populations are not thought to produce IFN-% we examined the 962  v  INTERFERON  ROLE  IN  T  CELL-REPLACING  FACTOR  ACTION 
TABLE  VII 
Human TRF(E-N) Supports Antigen-specific PFC Responses: Reversal by rlFN-'y of antibody- 
induced Inhibition  Is Also Antigen-specific 
Antigen in  TRF in culture  culture 
Antibody and/or IFN-3, added 
PFC per culture (SEM) mea- 
sured on: 
SRBC  BRBC 
Nolle  TRF(E-N)  None  72 (26)  0 
SRBC  TRF(E-N)  None  1,000 (79)  0 
BRBC  TRF(E-N)  None  73 (18)  618 (48) 
SRBC  TRF(E-N)  Anti-IFN-'y  300 (36)  8 (8) 
BRBC  TRF(E-N)  Anti-IFN-7  43 (15)  48 (10) 
SRBC  TRF(E-N) 
BRBC  TRF(E-N) 
Anti-IFN-~' plus Mu rlFN-'¢  953 (133)  0 
Anti-lFN-3, plus Mu rIFN-~,  10 (6)  405 
SRBC  TRF(E-N)  Mu rIFN-3'  878 (99)  2 
BRBC  TRF(E-N)  Mu rlFN-3,  53 (11)  510 
None  None  None  48 (10)  2 
SRBC  None  None  13 (6)  0 





T-depleted spleen cells were cultured with 2  X  106 SRBC or BRBC for 4  d  with additions to the 
cuhures as indicated. 25 U of rabbit antibody or 2,500 U of rIFN-3' were used. 
TABLE  VIII 
TRF(E-N) lnduces IFN-3, in T-depleted Spleen Cell Cultures 
Culture conditions 
Units* of IFN-~, 
Mean (SEM) 
Day of assay  PFC per 
culture 
1  2  3  4 
Medium  0  0  0  0  0 
SRBC  0  0  0  0  0 
TRF(E-N)  0  0  0  160  0 
TRF(E-N) +  RAM-IFN-~'  0  0  0  0  3 (3) 
TRF(E-N) +  SRBC  0  0  160  160  717 (88) 
TRF(E-N) +  SRBC +  RAM-IFN-'y  0  0  0  0  17 (3) 
Control: TRF(E-N) in the absence of cells, 0  U  IFN 
106 T-depleted spleen cells were cultured for variable periods of time in the presence of TRF, 
antigen, and antibody to IFN-3,, as indicated. Supernatants were pooled from triplicate wells and 
assayed for IFN-2~ levels. On day 4, cells from individual wells were assayed for PFC responses. 
RAM-IFN-3, was added to indicated cultures at 25 neutralizing units per culture. IFN activity was 
measured by inhibition of vesicular stomatitis virus cytopathic effects on L~ cell monolayers using 
serial twofold dilutions of supernatant. IFN-~,  was identified in each of the active supernatants by 
sensitivity to pH 2.0, and neutralization with monoclonal R4-6A2 antibody and RAM-IFN-3, serum, 
but not with RAH-IFN-'y antibody or antibody to Mu IFN-o~, -/3. The assays were standardized by 
inclusion of a control Mu 1FN-a, -/3 preparation (N 1H reference reagent No. G002-904-511). 
*  1 U of 1FN as determined in this assay is equivalent to 0.08 IU/ml. BRUNSWICK  AND  LAKE  963 
extent  of non-B  cell  contamination  in  the  spleen cell  cultures.  At  the  start  of 
culture, <1% (generally 0-0.6%) Thy-1.2 + cells were routinely detected, but, by 
day 4, 5-10% of the cells were Thy-1.2 +. Since NK cells and their precursors (a) 
show variable expression of Thy-1 (24), (b) proliferate and mature in cultures of 
T-depleted spleen cells in  the  presence of IL-2 (24),  and (c) produce abundant 
IFN-~, on  stimulation  with  human  (25)  or  murine  (26)  IL-2, we examined  the 
PFC cultures after 4  d  for NK cell activity.  As shown  in Table IX, a  dramatic 
appearance of NK cells is evident. This effect requires stimulation of the cultures 
with  TRF.  Lysis  of YAC-1,  but  not  P-388D1,  target  cells  confirmed  the  NK 
character of the effector cells. Thus, TRF(E-N) induces both IFN-3, production 
and the striking NK cell activity of T-depleted murine spleen cells. 
Time of Action  of IFN-'y in  the  TRF Assay.  To  investigate  the  time at  which 
human  TRF(E-N)  and  IFN-7  act  in  this  system,  we  measured  PFC  responses 
after adding  TRF(E-N)  at  different  times,  adding  antibody at  different  times, 
and  varying  the  time  of reversal  of inhibition  with  Mu  rIFN-%  As  shown  in 
Table X, TRF(E-N) was most active when included at the beginning of culture 
or at day 1. Antibody to Mu IFN-~ inhibited responses only if added very early. 
When antibody to  Mu  IFN-3, was added  on day  1,  only a  partial inhibition  was 
TABLE IX 
TRF(E-N) Induces the Maturation  of Potent NK Activity 
Lytic units  Lytic units after culture with: 
Exp. No.  Target cell  before cul-  SRBC plus 
ture  None  SRBC  TRF(E-N)  TRF(E-N) 
1  YAC-1  2  0.3  0.6  667  1,000 
2  YAC-1  4  7  5  196  147 
P-388DI  ND  0  4  11  4 
NK cell activity was examined in assay cultures using 104 YAC-1 or P-388D1 target cells labeled with 
5~Cr. Results are expressed in lytic units per 107 effector cells, as described in Materials and Methods. 
TABLE  X 
Kinetic Analysis of TRF Action and Inhibition With Antiserum to Mu IFN-7 
Addition to cultures  PFC (SEM) to SRBC per culture with variable 
component added on days: 
Variable compo-  0  1  2  3  Continuously present  nent 
Nil  Nil  0 
Nil  rlFN-7  6 (3)  0  0  3 (3) 
Nil  TRF(E-N)  2,157 (18)  2,153 (63)  423 (107)  3 (3) 
TRF(E-N)  Nil  1,917 (237) 
TRF(E-N)  RAM-IFN-7  273 (48)  1,153  (13)  2,017 (108)  2,077 (47) 
TRF (E-N) plus RAM-  Nil  427 (52) 
IFN--y 
TRF(E-N) plus RAM-  2,500 U rIFN-7  2,017 (110)  1,913  (185)  1,170  (119)  377 (26) 
IFN-'y 
T-depleted (DBA/2 x  CBA/N)F1 spleen cells were cultured  with SRBC for 4 d. At the start of the 
culture or at various times thereafter the indicated additions were made. 964  ~,  INTERFERON  ROLE  IN  T  CELL-REPLACING  FACTOR  ACTION 
obtained. Finally, in cultures where responses were inhibited by antibody to IFN- 
3", the responses recovered only when Mu rIFN-7 was added during the first 2 
d  of culture.  This  last result shows that the specific IFN-3,  component of the 
signal  for  TRF  activity  must  be  received early  in  the  response, and  that  it 
probably was responsible for the kinetics in the first two groups of results. 
The inhibition of TRF-supported responses by antibody to IFN-3" is apparently 
caused by a delay in the kinetics of the PFC response (Table XI). This result is 
expected if endogenous IFN-3, production by spleen cells can saturate the capacity 
of the inhibitory antibody and if a critical period for IFN-3" action has not lapsed. 
Discussion 
In this report we have examined the role of IFN-3,  in TRF-dependent PFC 
responses of murine spleen cells to  red blood cell antigens.  Several antibody 
preparations with high specific neutralizing activity for human and murine IFN- 
3' were added to  the cultures to test their effects on TRF action.  The results 
show that antibody to murine but not to human IFN-3,  can abrogate the TRF 
activity of either human, primate, or murine TRF preparations and that these 
inhibitions are reversed specifically by the addition  of excess murine but  not 
human recombinant-derived IFN-3,. 
Although  TRF  activity  was  described more  than  a  decade ago  (27),  until 
recently there had  been  little progress  in  the  molecular identification of the 
active factor(s), probably because,  as shown by new evidence, several distinct 
factors cooperate to mediate TRF effects. In addition to SRBC responses, TRF 
is active in the antibody responses of B cells to hapten-protein antigens (12) and 
thymus-independent antigens (13, 28) and in polyclonal activation of B cells by 
anti-Ig antibodies (4).  Thus, TRF appears to be the major cytokine-controlled 
regulatory pathway for  the expansion and  maturation  to  antibody-producing 
cells of a  major,  Lyb-5  + subpopulation  of B cells (29).  Studies (3,  8-10)  using 
new methods for lymphokine purification and Sn of long-term or cloned T  cell 
lines in factor reconstitution experiments have produced clear evidence for the 
presence of several required components in TRF. Collectively, the data indicate 
that, for the systems studied, at least two major components are involved: first, 
TABLE  XI 
Antibody to IFN-3, Delays the Generation of PFC 
Source of 
TRF 
Anti-  PFC per Culture (SEM) 
body to  Day of assay 
IFN-~' 
3  4  5  6 
TRF(E-N)  -  10 (6)  767 (171)  1,330 (91)  1,123 (105) 
TRF(E-N)  +  0  137 (72)  1,160 (57)  1,240 (77) 
Con ASn  -  0  977 (221)  1,090 (58)  55 (25) 
Con A Sn  +  0  153 (62)  750 (91)  990 (228) 
No TRF  -  0  0  7 (3)  7 (7) 
106 T-depleted spleen cells were cultured in the presence of the indicated 
source of TRF and 2 ×  106 SRBC. 25 neutralizing units of RAM-1FN-~ 
were added tO some cultures. Specific PFC were determined on the day 
indicated. Results are expressed as the mean PFC (SEM) per culture. BRUNSWICK  AND  LAKE  965 
an IL-2-containing Sn of T  cells, which may, however, include additional media- 
tors, and second, an IL-2-depleted Sn of Con A-activated spleen cells (8), which 
may also be replaced by secreted products of some T  cell lines (10,  11, 30).  In 
some studies,  IL-2-containing  Sn alone are active as TRF, possibly due to the 
activity of this  lymphokine on  contaminating  T  cells or other non-B cells (2); 
generally, however, TRF activity of IL-2 alone is not reported in other systems. 
Recent work has shown that the second component has an apparent molecular 
weight of 40,000 (8) and that its activity is most evident when added 24 h after 
the start of cultures (11,  12), as noted previously (31) for unfractionated  Sn of 
Con A-stimulated spleen cells. This second component was shown (1,  12,  14) to 
be sensitive to treatment at pH 2 and to correlate with IFN-3, activity in Sn of T 
cell lines. In a recent report (15) rIFN-3, showed similar biological activity. IFN- 
3' is already known to act as a  differentiation signal in several murine immuno- 
logical systems, such as the induction of major histocompatibility complex (MHC) 
antigens  (32),  the  activation  of mononuclear  phagocytes (17,  18,  33),  the  en- 
hancement  of NK  cell  activity  (25),  and  a  TRF-like  action  in  the  genesis  of 
cytotoxic T cells (34). However, the regulation of B cell differentiation represents 
a new and important biological function of IFN-3". 
To examine the role of IFN-3' in antibody responses supported by TRF, we 
used the same preparations of antibody to IFN-3" shown to functionally neutralize 
the antiviral and macrophage-activating factor (MAF) activity of IFN-3" (17,  18). 
Other antibodies to IFN-3, have been shown to abrogate TRF help for cytotoxic 
T  cells (35) and, recently, the induction of MHC class II antigens by IFN-3" was 
shown to be inhibited by antibody to IFN-3"  (19).  Experiments  using antibody- 
mediated  inhibition  are  able  to  demonstrate  a  necessary  role  for  a  specific 
lymphokine in a  mixture  of biologically active molecules in a  crude Sn.  In the 
present study, this method was able to determine whether IFN-3" is a  necessary 
component of TRF action, in a variety of TRF preparations.  Although previous 
reconstitution studies, using monoclonal cytokines or recombinant-derived pro- 
teins, support a role for IFN-3",  it is not clear that IFN-3" is normally a required 
component of TRF. It is possible that IFN-3" substitutes for, or bypasses the need 
for, other mediators present in TRF that normally support antibody responses. 
The results in the present study consistently show that strong, specific inhibitions 
are obtained using four independent sources of TRF, demonstrating that IFN-3" 
is consistently required for the activity of TRF. 
A  human,  IL-2-rich  lymphokine  fraction,  known  to  have  TRF  activity  on 
human  B cells (36), is herein  shown to be an effective TRF for murine  B cells 
and  to  resemble  murine  TRF,  in  magnitude,  kinetics,  and  specificity,  in  its 
support  of murine  PFC  responses  to  SRBC.  Moreover,  this  preparation  was 
inactive with  B cells from mice with the xid defect, as shown for murine  TRF 
(6),  suggesting that  common TRF pathways are followed. In view of the need 
for IFN-3" in the action of murine  TRF, as well as the species specificity of the 
biological actions of IFN-~ (18), it was surprising that human-derived TRF was 
active in this system. However, human  IFN-3, appears to have no role in these 
responses, since rabbit antibody to Hu  IFN-3, and  four monoclonal  antibodies 
with high Hu IFN-3, neutralizing activity (data not shown) did not suppress TRF 
activity, whereas antibody to Mu IFN-3" did inhibit PFC production. The specific 966  3"  INTERFERON  ROLE  IN  T  CELL-REPLACING  FACTOR  ACTION 
lymphokine target of this latter antibody was examined in several ways. First, we 
found  that  antiserum  to  Mu  IFN-3'  had  no effect on  human  IL-2  and  B  cell 
growth  factor  (BCGF)  in  their  respective  functional  assays  (data  not  shown). 
Second, the inhibited responses were restored by the addition of excess murine 
but not human rIFN-3'. Third, an antigen affinity-purified rabbit Ig, specific for 
Mu  rIFN-3',  was similarly  inhibitory.  This  result  indicates  that  the  inhibitions 
could be due solely to antibodies to Mu rIFN-3, rather than to other antibodies 
in  the  sera.  Fourth,  a  monoclonal  antibody  that  specifically neutralizes  the 
antiviral  effect of Mu  IFN-3, also abrogated  TRF activity, and  this  block was 
relieved with excess Mu IFN-3,. This result argues strongly that Mu IFN-3, is the 
target  lymphokine  of the  antibodies,  since  it  is  less  likely  that  a  monoclonal 
antibody would avidly crossreact with another  lymphokine (a possibility to be 
considered with polyvalent antisera). The finding that Hu rIFN-3' did not restore 
the response corresponds both with the specificity of the antisera and with the 
species specificity of its biological effects, e.g., it has no antiviral  activity when 
tested  in  murine  assays (18).  Moreover,  in  other  experiments,  the  functional 
activity of TRF(E-N) was unaltered after exposure to pH 2.0. 
The  reversal  of the  inhibition  of PFC  responses  upon  addition  of rIFN-3' 
suggests that quantitative relationships in this system may be complex. It appears 
that  >250  U  of IFN-3, are required  to reverse the inhibition  produced by 25 
neutralizing units of antibody. This discrepancy may occur because IFN-3, added 
at the initiation of the cultures may be substantially degraded or absorbed in the 
high  density cell cultures before its time Of action, which may extend to 48 h. 
Time-dependent  absorption of IFN-y in murine cell cultures has been demon- 
strated (37). 
Together,  our results argue that  IFN-3' is necessary in TRF action,  even in 
the case of a  TRF that  genetically lacks this factor; in  the latter circumstance, 
IFN-3" is produced by the cultured, T-depleted murine spleen cells. Recent work 
on the production of IFN-3' by spleen cells has shown that unfractionated spleen 
cells (38) as well as nu/nu  or conventional T-depleted spleen cells (25) produce 
IFN-~, upon culture in the presence of purified murine or human IL-2. NK cells 
appear to be a very adequate source of IFN-~, (26). In the present study (Table 
VIII), significant levels of Mu IFN-3, were recovered from the culture Sn after 
3-4 d.  Since some biological systems, e.g.,  MAF assays, are considerably more 
sensitive to IFN-3' than antiviral assays (18), it is possible that  IFN-3, concentra- 
tions  adequate  to  support  B  cell  responses are  present  at  earlier  times.  This 
possiblity is favored by the high local concentrations of IFN-3' that occur in cell- 
to-cell interactions.  It also appears that IFN-3, is not produced constitutively but 
is induced by TRF. The cellular source of this factor remains unclear but may 
be the T-related,  large granular  lymphocytes that  possess NK activity and are 
reduced but usually not fully eliminated  in  most T  cell depletions.  These cells 
may also comprise the component that permits TRF activity of FS6-14.13 Sn (2) 
or may be the novel helper cells postulated by Parker (10) to explain a possible 
mode of action of IL-2 in TRF-supported PFC responses in the anti-Ig system. 
Residual  T  cell  activity  in  T-depleted  spleen  cell  populations  has  been  well 
documented (10, 39). In the present study, high levels of NK cells were produced 
(Table  IX) after  4  d  of culture  in  the  presence  of TRF(E-N).  In  view of the BRUNSWICK AND  LAKE  967 
ability of these ceils to produce IFN-3, (25, 26), they may play a  crucial  role in 
TRF-mediated  B  cell  responses.  We  found  that  antibody  to  IFN-~,  did  not 
permanently inhibit TRF-supported anti-SRBC responses but rather delayed the 
appearance of PFC (Table XI). The similar magnitude of the intact and delayed 
responses suggests that the antibody acts as a transient sink for IFN-~, produced 
in the cultures, and that the antibody capacity is soon surpassed by endogenous 
IFN-3, production. 
In other experiments  (Table V), an  IL-2-rich  Sn  constitutively produced by 
the  Gibbon  T  cell  line  MLA-144  (supplied  by Dr.  H.  Rabin),  when  used at a 
similar dilution of IL-2 activity, was similar to TRF(E-N) for TRF activity. This 
result suggests that any potentially copurified but undetectable mitogens are not 
responsible  for  the  biological  effects of TRF(E-N).  Interestingly,  Mu  rIFN-3, 
showed no TRF activity in these experiments, either alone (Tables III and X) or 
in  the presence of suboptimal concentrations  of TRF(E-N) or TRF(MLA-144) 
(Tables IV and V). This suggests that IFN-'y is not limiting in the latter cultures 
or is functionally inactive but antigenically intact. The latter seems unlikely since 
the molecule was functional in several independent biological assays. The lack of 
TRF activity of IFN-? alone is consistent with the need for at least two factors 
for TRF activity, the second of which may be supplied by the IL-2-rich TRF(E- 
N). 
Our  data  do  not  address  the  role  of IL-2  itself  in  these  TRF-dependent 
responses.  IL-2  may act in  synergy with  IFN-'y, or it may,  secondarily, induce 
the production of IFN-'y (25, 26) and perhaps other factors such as BCGF (30, 
40). Alternatively,  it is possible that other factors, such as BCGF, that copurify 
with human  IL-2 (41) are directly involved in  these responses.  Human  IL-2 is 
known (10) to be active on murine T  cells and has been shown to replace murine 
IL-2  in  both  cell  expansion  and  antibody  production  by T-depleted  murine 
spleen cells (10). While most past studies have used IL-2-containing Sn of T  cell 
lines, which may contain other factors such as BCGF (1,  10, 42, 43) that may be 
needed for maximal responses, the affinity-purified human IL-2 used by Parker 
(10) argues most strongly for a  role of IL-2 in the TRF system. This role may 
be direct  and  necessary, such as a  signal  for  B  cell  differentiation,  or may be 
indirect, such as inducing other factors that are the ultimate mediators of signals 
needed for B cells. The production of secondary mediators induced by IL-2, or 
by TRF, as in the present study, may account for some of the differing results 
concerning the controversial role for IL-2 in TRF action.  Such effects could be 
variable and may depend significantly on the purity of the cells and the factors 
used (3,  28).  A  recently described (19) intermediate  modulator  for Ia antigen 
expression  induced  by  IFN-'y  is  an  example  of this  concept.  Some  of these 
uncertainties could be resolved in studies with monoclonal antibodies that neu- 
tralize  the  activity  of  specific  lymphokines  such  as  BCGF,  IL-1,  and  IL-2. 
Alternatively,  antibodies  to  the  cellular  receptors  for  these  lymphokines  may 
serve the same purpose, and help to identify the cell subsets involved. Single-cell 
assays maY be the most useful way to analyze the distinct action of lymphokines 
on B cells. Such cultures would be free of the products of all forms of accessory 
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Summary 
The role of gamma interferon (IFN-~,) in T  ceil-replacing factor (TRF) activity 
for  antigen-specific  plaque-forming cell  (PFC)  responses  in  vitro  was  studied 
using  antibodies  to  murine  IFN-~,  (Mu  IFN-~).  TRF  activity was  present  in 
supernatants  (Sn)  of Con  A-  or  mixed  leukocyte reaction-stimulated  murine 
spleen cells as well as in an IL-2-rich fraction of phytohemagglutinin-stimulated 
human peripheral blood lymphocyte Sn and in the Sn of the Gibbon T  lymphoma 
MLA-144. The human TRF was highly active with cells from nu/nu mice and 
normal mice but not with cells from animals with the xid  immunologic defect, 
similar to the activity of murine TRF. Antibodies to IFN-3, consisted of hyper- 
immune rabbit antisera, IFN-~, affinity-purified rabbit immunogiobulin and an 
interspecies hybridoma specific for Mu IFN-% The results show that the activities 
of all preparations of TRF are markedly diminished or abrogated by antibody 
to Mu IFN--y but not by antibodies to human IFN-3, (Hu IFN-3,), nor by normal 
rabbit sera or purified rabbit Ig. The degree of inhibition was dose dependent 
and was quantitatively reversed by the addition to the cultures of recombinant- 
derived  Mu  IFN-"y (Mu  rIFN-3,)  but  not  Hu  rIFN-%  This reversal  was  fully 
antigen specific and thus not attributable to polyclonal B cell activation by IFN- 
%  which is inactive alone in the TRF assay. Kinetic analysis shows that IFN-~, 
must  act  by  24-48  h  to  produce  PFC  responses  at  4  d.  Together,  the  data 
demonstrate that IFN-~' is a necessary mediator for TRF effects and that IFN-3, 
is induced by TRF from T-depleted murine spleen cells in sufficient quantity to 
support large antibody responses.  The source of this IFN-~"  may be the potent 
natural killer cells that are induced in cultures stimulated with TRF. 
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